Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Marketing Value Of Abuse-Deterrent Labeling Weighed At Vantrela Review

Related Content

Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.

May 14 2007

When Is An Abuse-Deterrent Claim FDA Approved?

Jun 20 2016

Related Companies

Teva Pharmaceutical Industries Ltd.

Zyla Life Sciences

Endo, Inc.

Zevra Therapeutics, Inc.

Purdue Pharma L.P.

Pfizer Inc.

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window